The groundbreaking rise of Viagra has consistently remained a symbol of pharmaceutical success, but its legacy within the broader sector now triggers questions about long-term returns . Copycat versions are undercutting patent protection , leading to worries that investing in companies heavily reliant to Viagra's once-dominant position could be a d